Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Solstice raises $21M in Series A led by Transformation Capital to enhance pharma commercialization and cut marketing review cycles to under 48 hours.
RECENTLY ACQUIREDMay 28, 2026•2 months ago
Amount Raised
$21 Million
Round Type
Series A
Investors
Virtue VenturesTwelve BelowTransformation Capital
Description
Solstice has raised $21 million in Series A funding led by Transformation Capital, with participation from Twelve Below, Virtue Ventures, and others. This investment will support go-to-market expansion and boost product development. The funding aims to significantly reduce the time it takes to bring marketing campaigns to market in the pharma industry. Solstice's innovative approach is poised to transform the way biopharma companies approach commercialization.
Related People
Suggested for you
2 contactsVerified contactsCaroline K., Managing Director EVP International Bus… hidden hidden
Funding Insights
Based on industry dataTypical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech